Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Amino Acids 22(4):381389 Meinen S, Lin S, Regg MA, Punga AR (2012) Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS
MGF is a peptide shows potential and involvement of in muscle repair and growth
Inflammatory Phase Management Excessive or prolonged inflammation contributes to abnormal scarring, including hypertrophic scars and keloids
FDA to consider lifting restrictions on peptide injections (Scott Brunner quote) GlobalData / Fierce Pharma, March 2024
Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models
Rather than raising NAD+ systemically (as NMN or NR supplementation does), NNMT inhibition preserves NAD+ specifically in the tissue where metabolic dysfunction is most pronounced a precision approach that appeals to researchers studying tissue-specific metabolic regulation
